A5025681628- Platelet Disorders and Treatments
- Venous Thromboembolism Diagnosis and Management
- Heparin-Induced Thrombocytopenia and Thrombosis
- Hemophilia Treatment and Research
- Atrial Fibrillation Management and Outcomes
- Blood groups and transfusion
- Blood Coagulation and Thrombosis Mechanisms
- COVID-19 Clinical Research Studies
- Intramuscular injections and effects
- Clinical practice guidelines implementation
- Antiplatelet Therapy and Cardiovascular Diseases
- Blood donation and transfusion practices
- Long-Term Effects of COVID-19
- Meta-analysis and systematic reviews
- Acute Myocardial Infarction Research
- Health Systems, Economic Evaluations, Quality of Life
- SARS-CoV-2 and COVID-19 Research
- Case Reports on Hematomas
- Blood transfusion and management
- Chronic Myeloid Leukemia Treatments
- Complement system in diseases
- Trauma and Emergency Care Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Maternal and fetal healthcare
- COVID-19 and healthcare impacts
McMaster University
2015-2024
Hamilton Regional Laboratory Medicine Program
2009-2024
Hamilton Health Sciences
2005-2024
St. Joseph’s Healthcare Hamilton
2010-2023
Hamilton General Hospital
2011-2022
University of Toronto
2004-2021
University Health Network
2019-2021
Thrombosis and Atherosclerosis Research Institute
2014-2021
Health Sciences Centre
2007-2019
Women's College Hospital
2019
Background: Coronavirus disease 2019 (COVID-19)–related critical illness and acute are associated with a risk of venous thromboembolism (VTE). Objective: These evidence-based guidelines the American Society Hematology (ASH) intended to support patients, clinicians, other health care professionals in decisions about use anticoagulation for thromboprophylaxis patients COVID-19–related who do not have confirmed or suspected VTE. Methods: ASH formed multidisciplinary guideline panel applied...
Venous thromboembolism (VTE) is a common preventable cause of mortality in hospitalized medical patients. Despite rigorous randomized trials generating strong recommendations for anticoagulant use to prevent VTE, nearly 40% patients receive inappropriate thromboprophylaxis. Knowledge-translation strategies are needed bridge this gap. We conducted 16-week pilot cluster controlled trial (RCT) determine the proportion that were appropriately managed thromboprophylaxis (according American...
Abstract The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear. Although most randomized controlled trials have shown negative results, uncontrolled studies suggested that the antibody content could influence patient outcomes. We conducted an open-label, trial adults with COVID-19 receiving oxygen within 12 d respiratory symptom onset ( NCT04348656 ). Patients were allocated 2:1 to 500 ml or standard care. composite primary outcome was intubation death by 30...
Despite an increase in our understandings of pathogenesis thrombotic thrombocytopenic purpura (TTP), the approaches for initial diagnosis and management TTP vary significantly.The evidence-based guidelines International Society on Thrombosis Haemostasis (ISTH) are intended to support patients, clinicians, other health care professionals their decisions about acute TTP.In June 2018, ISTH formed a multidisciplinary panel that included hematologists, intensive physician, nephrologist, clinical...
Objectives: To identify risk factors for failure of anticoagulant thromboprophylaxis in critically ill patients the ICU. Design: Multivariable regression analysis thrombosis predictors from a randomized trial. Setting: Sixty-seven medical-surgical ICUs six countries. Patients: Three thousand seven hundred forty-six patients. Interventions: All received with low-molecular-weight heparin or unfractionated at standard doses. Measurements and Main Results: Independent venous thromboembolism,...
Heparin-induced thrombocytopenia is an uncommon condition mediated by anti-PF4 platelet-activating antibodies that typically begins 5–14 days after heparin initiation. Overall, greater risk associated with unfractionated than low-molecular-weight heparin.[1][1] The platelet count
This is a revision of the online November 2021 Brighton thrombosis with thrombocytopenia syndrome (TTS) case definition and new Collaboration for vaccine-induced immune (VITT). These definitions are intended use in clinical trials post-licensure pharmacovigilance activities to facilitate safety data comparability across multiple settings. They not guide management. The were developed by group subject matter process experts as part Coalition Epidemic Preparedness Innovations (CEPI)-funded...
Platelet dense granule release assays are recommended for diagnosing platelet function disorders and commonly performed by Lumi-Aggregometer (Chrono-Log, Havertown, PA) of adenosine triphosphate (ATP) release. We conducted a prospective cohort study people tested ATP defects to assess bleeding symptoms. Reduced release, with 1 or more agonists, was common among patients than healthy control subjects (P < .001). The respective likelihood (odds ratio [95% confidence interval]) disorder an...
Rare diseases are a global public health priority. Though each disease is rare, when taken together the thousands of known rare cause significant morbidity and mortality, impact quality life, confer social economic burden on families communities. These conditions are, by their nature, encountered very infrequently individual clinicians, who may feel unprepared to address diagnosis treatment. Clinical practice guidelines necessary support clinical policy decisions. However, creating for...
Summary To determine whether the factor V Leiden mutation is associated with decreased bleeding in individuals severe hemophilia A, concentrate utilization, maximum annual number of episodes, and prevalence hemophilic arthropathy between carriers non-carriers were compared. Heterozygosity for was found 6 137 subjects (4.4%). Carriers utilized less (geometric mean: 310 vs. 1185 units/kg/year) had fewer episodes than (proportion 10 or their worst year: 50 11%). However, not absence...
A comprehensive multi-attribute system was devised to assess global morbidity burden. The used obtain qualitative and quantitative measures of health-status for a case series survivors brain tumors in childhood. Health-related quality-of-life scores each health-state were calculated from utility function derived preferences collected during surveys random sample parents school age children the general public (n=194). Global health status (MAHS) revealed wide range severity We suggest that...